“As we have accustomed our shareholders, we are continuing to accelerate the company’s expansion and development plan and announce a new acquisition, marking the entrance to the outpatient segment in a new area of Romania. In the future we will continue to strengthen our position at national level both through acquisitions and green field projects,” said Mihai Marcu, president and CEO of MedLife.
The Solomed Group was set up in 1997 and is one of the leading local medical operators in the region. The group consists of five clinics – three in Pitesti, the other two in Costesti and Curtea de Arges – and a laboratory (Pitesti), offering patients a wide range of investigations from multidisciplinary consultations and laboratory services, to CT investigations, ultrasounds; medical recovery services and small laser interventions. The medical units are equipped with state-of-the-art medical equipment and have a medical team of over 90 specialists.
Solomed registered a turnover of approximately RON5.2 million in 2017, according to its representatives.
The acquisition of Solomed’s majority stake is MedLife’s 19th acquisition to date.
MedLife reported a pro-consolidated RON638 million turnover in 2017, up 27% compared with 2016, and an adjusted EBITDA pro-forma of RON82.3 million.
For 2018, the company targets an increase of over 20%.